Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BEAM Beam Therapeutics	$30.62 +17.9%	$21.57	$13.52 ▼ $35.25	$2.63B	2.25	2.23 million shs	4.80 million shs
MRNA Moderna	$27.24 +4.7%	$25.94	$23.15 ▼ $57.69	$10.16B	2.01	9.66 million shs	11.49 million shs
PFE Pfizer	$24.68 +0.7%	$24.89	$20.92 ▼ $29.22	$139.35B	0.55	61.16 million shs	35.81 million shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BEAM Beam Therapeutics	+17.86%	+20.60%	+25.90%	+42.15%	+29.47%
MRNA Moderna	+4.73%	+1.87%	+7.92%	-16.77%	-49.65%
PFE Pfizer	+0.68%	-0.14%	+2.71%	-1.77%	-15.53%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BEAM Beam Therapeutics	$30.62 +17.9%	$21.57	$13.52 ▼ $35.25	$2.63B	2.25	2.23 million shs	4.80 million shs
MRNA Moderna	$27.24 +4.7%	$25.94	$23.15 ▼ $57.69	$10.16B	2.01	9.66 million shs	11.49 million shs
PFE Pfizer	$24.68 +0.7%	$24.89	$20.92 ▼ $29.22	$139.35B	0.55	61.16 million shs	35.81 million shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BEAM Beam Therapeutics	+17.86%	+20.60%	+25.90%	+42.15%	+29.47%
MRNA Moderna	+4.73%	+1.87%	+7.92%	-16.77%	-49.65%
PFE Pfizer	+0.68%	-0.14%	+2.71%	-1.77%	-15.53%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BEAM Beam Therapeutics	2.94	Moderate Buy	$45.92	49.96% Upside
MRNA Moderna	2.00	Hold	$39.93	46.58% Upside
PFE Pfizer	2.39	Hold	$28.13	13.95% Upside

Current Analyst Ratings Breakdown

Latest PFE, MRNA, and BEAM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/20/2025	MRNA Moderna	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold
10/10/2025	PFE Pfizer	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Equal Weight	$33.00 ➝ $32.00
10/10/2025	BEAM Beam Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$80.00
10/10/2025	MRNA Moderna	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$31.00 ➝ $32.00
10/9/2025	BEAM Beam Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$48.00 ➝ $46.00
10/9/2025	BEAM Beam Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Hold ➝ Buy	$41.00
10/8/2025	BEAM Beam Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
10/8/2025	MRNA Moderna	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
10/8/2025	PFE Pfizer	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C-)
10/3/2025	PFE Pfizer	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$28.00 ➝ $30.00
10/1/2025	PFE Pfizer	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral	$28.00

(Data available from 10/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BEAM Beam Therapeutics	$63.52M	48.76	N/A	N/A	$8.86 per share	3.46
MRNA Moderna	$3.24B	3.29	N/A	N/A	$28.33 per share	0.96
PFE Pfizer	$63.83B	2.20	$4.39 per share	5.62	$15.62 per share	1.58

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BEAM Beam Therapeutics	-$376.74M	-$4.50	N/A	N/A	N/A	-661.31%	-43.15%	-31.06%	11/4/2025 (Estimated)
MRNA Moderna	-$3.56B	-$7.53	N/A	N/A	N/A	-94.31%	-25.96%	-20.09%	11/6/2025 (Estimated)
PFE Pfizer	$8.03B	$1.88	13.13	8.15	0.81	16.84%	21.42%	9.12%	11/4/2025 (Estimated)

Latest PFE, MRNA, and BEAM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/6/2025	Q3 2025	MRNA Moderna	-$1.95	N/A	N/A	N/A	$893.29 million	N/A
11/4/2025	Q3 2025	BEAM Beam Therapeutics	-$1.03	N/A	N/A	N/A	$12.83 million	N/A
11/4/2025	Q3 2025	PFE Pfizer	$0.79	N/A	N/A	N/A	$16.94 billion	N/A
8/5/2025	Q2 2025	BEAM Beam Therapeutics	-$1.04	-$1.00	+$0.04	-$1.00	$13.29 million	$8.47 million
8/5/2025	Q2 2025	PFE Pfizer	$0.58	$0.78	+$0.20	$0.51	$13.43 billion	$14.65 billion
8/1/2025	Q2 2025	MRNA Moderna	-$2.99	-$2.13	+$0.86	-$2.13	$116.26 million	$142.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BEAM Beam Therapeutics	N/A	N/A	N/A	N/A	N/A
MRNA Moderna	N/A	N/A	N/A	N/A	N/A
PFE Pfizer	$1.72	6.97%	N/A	91.49%	16 Years

Latest PFE, MRNA, and BEAM Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
10/9/2025	PFE Pfizer	quarterly	$0.43	6.82%	11/7/2025	11/7/2025	12/1/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BEAM Beam Therapeutics	N/A	6.75	6.75
MRNA Moderna	N/A	3.93	3.77
PFE Pfizer	0.65	1.16	0.85

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BEAM Beam Therapeutics	99.68%
MRNA Moderna	75.33%
PFE Pfizer	68.36%

Insider Ownership

Company	Insider Ownership
BEAM Beam Therapeutics	3.50%
MRNA Moderna	10.90%
PFE Pfizer	0.06%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BEAM Beam Therapeutics	510	101.16 million	97.62 million	Optionable
MRNA Moderna	5,800	390.58 million	348.01 million	Optionable
PFE Pfizer	81,000	5.69 billion	5.68 billion	Optionable

PFE, MRNA, and BEAM Headlines

Recent News About These Companies

Pfizer's Q3 Non-Oncology Performance: Here's What to Expect

October 20 at 11:15 AM | zacks.com

Bogart Wealth LLC Increases Stake in Pfizer Inc. $PFE

October 20 at 7:13 AM | marketbeat.com

Schnieders Capital Management LLC Lowers Stake in Pfizer Inc. $PFE

October 20 at 6:59 AM | marketbeat.com

CORDA Investment Management LLC. Raises Stock Position in Pfizer Inc. $PFE

October 20 at 6:59 AM | marketbeat.com

Birmingham Capital Management Co. Inc. AL Sells 30,994 Shares of Pfizer Inc. $PFE

October 20 at 6:49 AM | marketbeat.com

Astellas, Pfizer announces results from Phase 3 EV-303 trial for PADCEV

October 19 at 9:20 PM | msn.com

Pfizer Inc. $PFE Shares Sold by Northeast Investment Management

October 19 at 6:58 AM | marketbeat.com

Pfizer’s BRAFTOVI® + MEKTOVI® Shows Sustained Long-Term Survival in Patients with Advanced Lung Cancer

October 19 at 6:55 AM | cadillacnews.comC

John G Ullman & Associates Inc. Has $3.65 Million Stock Holdings in Pfizer Inc. $PFE

October 19 at 6:13 AM | marketbeat.com

Violich Capital Management Inc. Sells 10,200 Shares of Pfizer Inc. $PFE

October 19 at 6:06 AM | marketbeat.com

Pfizer Inc. $PFE Shares Sold by International Assets Investment Management LLC

October 19 at 5:47 AM | marketbeat.com

Foster & Motley Inc. Has $3.44 Million Stock Position in Pfizer Inc. $PFE

October 19 at 4:57 AM | marketbeat.com

XTANDI® Plus Leuprolide Reduced Risk of Death by 40% vs Leuprolide Alone in Men with a Type of Advanced Prostate Cancer

October 19 at 4:15 AM | businesswire.com

Pfizer's BRAFTOVI® + MEKTOVI® Shows Sustained Long-Term Survival in Patients with Advanced Lung Cancer

October 19 at 2:30 AM | businesswire.com

What Pfizer (PFE)'s Phase 3 Oncology Advances Mean for Shareholders

October 18 at 3:52 PM | finance.yahoo.com

Pfizer, Merck And Astellas Have An 'Enormous New Hope' For Bladder Cancer Patients

October 18 at 12:01 PM | investors.com

Astellas-Pfizer's combination therapy halves risk of death in bladder cancer patients

October 18 at 10:37 AM | reuters.com

PADCEV™ Plus KEYTRUDA™, Given Before and After Surgery, Cuts the Risk of Recurrence, Progression or Death by 60% and the Risk of Death by 50% for Certain Patients with Bladder Cancer

October 18 at 10:30 AM | prnewswire.com

Did Pfizer Overpay For Yet Another Acquisition?

October 18 at 9:50 AM | seekingalpha.com

Pfizer: World-Leading Drug Pipeline Sets Stage For Major Long-Term Potential

October 18 at 8:51 AM | seekingalpha.com

Arnhold LLC Boosts Stock Holdings in Pfizer Inc. $PFE

October 18 at 7:00 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

PFE, MRNA, and BEAM Company Descriptions

Beam Therapeutics NASDAQ:BEAM

$30.62 +4.64 (+17.86%)

Closing price 10/20/2025 04:00 PM Eastern

Extended Trading

$30.75 +0.13 (+0.42%)

As of 10/20/2025 07:58 PM Eastern

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Moderna NASDAQ:MRNA

$27.24 +1.23 (+4.73%)

Closing price 10/20/2025 04:00 PM Eastern

Extended Trading

$27.38 +0.14 (+0.51%)

As of 10/20/2025 07:59 PM Eastern

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Pfizer NYSE:PFE

$24.68 +0.17 (+0.70%)

Closing price 10/20/2025 03:59 PM Eastern

Extended Trading

$24.70 +0.02 (+0.09%)

As of 10/20/2025 07:59 PM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PFE, MRNA, and BEAM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PFE, MRNA, and BEAM Earnings

Compare Dividends

Latest PFE, MRNA, and BEAM Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PFE, MRNA, and BEAM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

PFE, MRNA, and BEAM Company Descriptions

Beam Therapeutics NASDAQ:BEAM

Moderna NASDAQ:MRNA

Pfizer NYSE:PFE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PFE, MRNA, and BEAM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PFE, MRNA, and BEAM Earnings

Compare Dividends

Latest PFE, MRNA, and BEAM Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PFE, MRNA, and BEAM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

PFE, MRNA, and BEAM Company Descriptions

Beam Therapeutics NASDAQ:BEAM

Moderna NASDAQ:MRNA

Pfizer NYSE:PFE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools